Allergan announces Vraylar’s availability

DUBLIN — Allergan on Wednesday announced the availability of its Vraylar (cariprazine) in the United States. The drug is a once-daily atypical antipsychotic indicated to treat acute manic or mixed bipolar I disorder episodes and schizophrenia in adults. 

 

The drug will be available in 30-count bottles of 1.5-, 3-, 4.5- and 6-mg dosage strengths, as well as a seven-count blister pack containing one 1.5-mg tablet and six 3-mg tablets. 

 

“We are excited that Vraylar is now available to the millions of people living with bipolar I disorder and schizophrenia,” said David Nicholson, President and EVP, Global R&D at Allergan. “This launch reinforces Allergan's rich heritage in mental health and our ongoing commitment to developing treatment options that address unmet needs for people who are affected by these serious conditions.”

 

The drug comes with a boxed warning for the risk of increased mortality in elderly patients who have dementia related psychosis.